Patch Testing in Non-Immediate Drug Eruptions
Tóm tắt
The present review addresses the literature regarding the sensitivity and specificity of the various diagnostic methods for evaluating non-immediate (ie, occurring more than 1 hour after drug administration) hypersensitivity reactions associated with β-lactams and other antibiotics, anticonvulsants, heparins, iodinated contrast media, etc. Such reactions include several clinical entities, which range from mild reactions, such as maculopapular rash and delayed-appearing urticaria, to severe ones, such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN). Clinical and laboratory studies indicate that a cell-mediated pathogenic mechanism is often involved in maculopapular rashes. However, this mechanism has also been demonstrated in other non-immediate reactions, such as urticarial and/or angioedematous manifestations, TEN, bullous exanthems, and AGEP. Patch tests, together with delayed-reading intradermal tests, lymphocyte transformation tests, and challenges, are useful tools for evaluating non-immediate drug eruptions. Patch tests can be performed with any form of commercial drugs and are safer than intradermal tests. However, patch tests are less sensitive than intradermal tests, and their sensitivity may vary, depending on the vehicle used.
Từ khóa
Tài liệu tham khảo
Romano A, Quaratino D, Di Fonso M: A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins. J Allergy Clin Immunol. 1999, 103: 1186-90. 10.1016/S0091-6749(99)70197-1.
Bocquet H, Bagot M, Roujeau J-C: Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms-DRESS). Semin Cutan Med Surg. 1996, 15: 250-7. 10.1016/S1085-5629(96)80038-1.
Posadas S, Pichler WJ: Delayed drug hypersensitivity reactions--new concepts. Clin Exp Allergy. 2007, 37: 989-99. 10.1111/j.1365-2222.2007.02742.x.
Romano A, Torres MJ, Quaratino D: Diagnostic evaluations of delayed hypersensitivity to systemically administered drugs. Allergy. 1999, 54 (Suppl 58): 23-7.
Barbaud A, Gonçalo M, Bruynzeel D, Bircher A: Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001, 45: 321-8. 10.1034/j.1600-0536.2001.450601.x.
Brockow K, Romano A, Blanca M: General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002, 57: 45-51. 10.1034/j.1398-9995.2002.13027.x.
Romano A, Blanca M, Torres MJ: Diagnosis of nonimmediate reactions to β-lactam antibiotics. Allergy. 2004, 59: 1153-60. 10.1111/j.1398-9995.2004.00678.x.
Phillips EJ, Wong GA, Kaul R: Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005, 19: 979-81. 10.1097/01.aids.0000171414.99409.fb.
Dooms-Goossens A, Verschaeve H, Degreef H, van Berendrocks J: Contact allergy to hydrocortisone and tixocortol pivalate: problems in detection of corticosteroid sensitivity. Contact Dermatitis. 1986, 14: 94-102. 10.1111/j.1600-0536.1986.tb01168.x.
Rosso R, Mattiacci G, Bernardi ML: Very delayed reactions to β-lactam antibiotics. Contact Dermatitis. 2000, 42: 293-5.
Gonçalo M, Oliveira HS, Monteiro C: Allergic and systemic contact dermatitis from estradiol. Contact Dermatitis. 1999, 40: 58-9. 10.1111/j.1600-0536.1999.tb05989.x.
Aberer W, Bircher A, Romano A: Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003, 58: 854-63. 10.1034/j.1398-9995.2003.00279.x.
Romano A, Viola M, Mondino C: Diagnosing nonimmediate reactions to penicillins by in vivo tests. Int Arch Allergy Immunol. 2002, 129: 169-74. 10.1159/000065876.
Aihara M, Ikezawa Z: Evaluation of the skin test reactions with delayed type rash induced by penicillins and cephalosporins. J Dermatol. 1987, 14: 440-8.
Terrados S, Blanca M, Garcia J: Nonimmediate reactions to betalactams: prevalence and role of the different penicillins. Allergy. 1995, 50: 563-7. 10.1111/j.1398-9995.1995.tb01200.x.
Luque I, Leyva L, Torres MJ: In vitro T-cell responses to β-lactam drugs in immediate and nonimmediate allergic reactions. Allergy. 2001, 56: 611-8. 10.1034/j.1398-9995.2001.000115.x.
Lammintausta K, Kortekangas-Savolainen O: The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol. 2005, 152: 968-74. 10.1111/j.1365-2133.2005.06429.x.
López Serrano C, Vilas F, Cabañas R, Contreras J: Delayed hypersensitivity to β-lactams. J Invest Allergol Clin Immunol. 1994, 4: 315-9.
Alanko K: Topical provocation of fixed drug eruption. A study of 30 patients. Contact Dermatitis. 1994, 31: 25-7. 10.1111/j.1600-0536.1994.tb01900.x.
Lee AY: Topical provocation in 31 cases of fixed drug eruption: change of causative drugs in 10 years. Contact Dermatitis. 1998, 38: 258-60. 10.1111/j.1600-0536.1998.tb05739.x.
Schmid DA, Depta JP, Pichler WJ: T cell-mediated hypersensitivity to quinolones. Clin Exp Allergy. 2006, 36: 59-69. 10.1111/j.1365-2222.2006.02402.x.
Romano A, Pettinato R, Andriolo M: Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr Pharm Des. 2006, 12: 3373-81. 10.2174/138161206778193962.
Motley RJ, Reynolds AJ: Carbamazepine and patch testing [letter]. Contact Dermatitis. 1989, 21: 285-6. 10.1111/j.1600-0536.1989.tb03221.x.
Osawa J, Naito S, Aihara M: Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol. 1990, 17: 235-9.
Prens EP, Troost RJJ, van Parys JAP: The value of the lymphocyte proliferation assay in detection of carbamazepine allergy. Contact Dermatitis. 1990, 23: 292-10.1111/j.1600-0536.1990.tb05136.x.
Alanko K: Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis. 1993, 29: 254-7. 10.1111/j.1600-0536.1993.tb03560.x.
Troost RJJ, van Parys JAP, Hooijkaas H: Allergy to carbamazepine: parallel in vivo and in vitro detection. Epilepsia. 1996, 37: 1093-9. 10.1111/j.1528-1157.1996.tb01030.x.
Lee AY, Choi J, Chey WY: Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis. 2003, 48: 137-9. 10.1034/j.1600-0536.2003.00065.x.
Vaillant L, Camenen I, Lorette G: Patch testing with carbamazepine: reinduction of an exfoliative dermatitis [letter]. Arch Dermatol. 1989, 125: 299-10.1001/archderm.125.2.299b.
Wütschert R, Piletta P, Bounameaux H: Adverse skin reactions to low molecular weight heparins. Drug Saf. 1999, 20: 515-25. 10.2165/00002018-199920060-00005.
Koch P, Münssinger T, Rupp-John C, Uhl K: Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractioned and low-molecular weight heparins: tolerance of a new recombinant hirudins. J Am Acad Dermatol. 2000, 42: 612-9. 10.1016/S0190-9622(00)90173-7.
Bircher AJ, Harr T, Hohenstein L, Tsakiris DA: Hypersensitivity reactions to anticoagulant drugs. Allergy. 2006, 61: 1432-40. 10.1111/j.1398-9995.2006.01227.x.
Christiansen C: Late-onset allergy-like reactions to x-ray contrast media. Curr Opin Allergy Clin Immunol. 2002, 2: 333-9. 10.1097/00130832-200208000-00007.
Brockow K, Christiansen C, Kanny G: Management of hypersensitivity reactions to iodinated contrast media. Allergy. 2005, 60: 150-8. 10.1111/j.1398-9995.2005.00745.x.
Guéant-Rodriguez RM, Romano A, Barbaud A: Hypersensitivity reactions to iodinated contrast media. Curr Pharm Des. 2006, 12: 3359-72. 10.2174/138161206778193999.
Vernassiere C, Trechot P, Commun N: Low negative predictive value of skin tests in investigating delayed reactions to radio-contrast media. Contact Dermatitis. 2004, 50: 359-66. 10.1111/j.0105-1873.2004.00367.x.
Dooms-Goossens A, Morren M: Results of routine patch tests with corticosteroid series in 2073 patients. Contact Dermatitis. 1992, 26: 182-91. 10.1111/j.1600-0536.1992.tb00290.x.
Matura M, Goossens A: Contact allergy to corticosteroids. Allergy. 2000, 55: 698-704. 10.1034/j.1398-9995.2000.00121.x.
Whitmore SE: Delayed systemic allergic reactions to corticosteroids. Contact Dermatitis. 1995, 32: 193-8. 10.1111/j.1600-0536.1995.tb00668.x.
Ventura MT, Calogiuri GF, Muratore L: Cross-reactivity in cell-mediated and IgE-mediated hypersensitivity to glucocorticoids. Curr Pharm Des. 2006, 12: 3383-91. 10.2174/138161206778194006.
Padial A, Posadas S, Torres MJ: Nonimmediate reactions to systemic corticosteroids suggest an immunological mechanism. Allergy. 2005, 60: 665-70. 10.1111/j.1398-9995.2005.00749.x.
Isaksson M, Bruze M, Goossens A, Lepoittevin JP: Patch testing with budesonide in serial dilutions: the significance of dose, occlusion time and reading time. Contact Dermatitis. 1999, 40: 24-31. 10.1111/j.1600-0536.1999.tb05972.x.
Wilkinson SM, Beck HM: Corticosteroid contact hypersensitivity: what vehicle and concentration?. Contact Dermatitis. 1996, 34: 305-8. 10.1111/j.1600-0536.1996.tb02212.x.
Dooms-Goossens A: Corticosteroid contact allergy: a challenge to patch testing. Am J Contact Dermatitis. 1993, 4: 120-6.
Herbst RA, Lauerma AI, Maibach HI: Intradermal testing in the diagnosis of allergic contact dermatitis: a reappraisal. Contact Dermatitis. 1993, 29: 1-5. 10.1111/j.1600-0536.1993.tb04527.x.
Barbaud A, Reichert-Penetrat S, Tréchot P: The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998, 139: 49-58. 10.1046/j.1365-2133.1998.02313.x.